by Maria Zannes | Mar 12, 2019 | Press Releases
MARCH 12, 2019 (San Antonio, TX) bioAffinity Technologies, a privately held biotech company, today announced the formation of a Scientific and Medical Advisory (SMA) Board to provide independent expert advice and counsel on the Company’s research and development of...
by Maria Zannes | Mar 6, 2019 | Press Releases
MARCH 6, 2019 (San Antonio, TX) Healthcare innovators Lyfebulb and Helsinn selected bioAffinity Technologies, a privately held biotech company developing diagnostics and therapeutics for cancer, as one of 10 finalists for the second annual in Oncology. The Innovation...
by Maria Zannes | Feb 5, 2019 | Press Releases
FEBRUARY 4, 2019 (San Antonio, TX) bioAffinity Technologies, a privately held biotech company, announced that the Canadian Intellectual Property Office has awarded a patent expanding the Company’s claims associated with its proprietary CyPath© technology for the early...
by Maria Zannes | Oct 23, 2018 | Press Releases
OCTOBER 23, 2018 (San Antonio, TX) bioAffinity Technologies, a privately held biotech company, today announced that the South Texas Veterans Health Care System (STVHCS), which is affiliated with the federal Department of Veterans Affairs (VA) health care system, will...
by Maria Zannes | Oct 12, 2018 | Press Releases
OCTOBER 10, 2018 (San Antonio, TX) bioAffinity Technologies, a privately held biotech company, today announced a licensing agreement with Precision Pathology Services for the continued development and commercial sale of CyPath® Lung as a Laboratory Developed Test...
by Maria Zannes | Sep 22, 2018 | Press Releases
SEPTEMBER 18, 2018 (San Antonio, TX) bioAffinity Technologies, a privately held biotech company, today announced that the Icahn School of Medicine at Mount Sinai (ISMMS) in New York, NY, will be a clinical collection site for the Company’s test validation trial of...
